- Conditions
- Advanced Solid Tumor
- Interventions
- STX-001, Keytruda®
- Biological
- Lead sponsor
- Strand Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Cleveland, Ohio + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 398
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Hepatitis C
- Interventions
- ANA598 200 mg bid or placebo, ANA598 400 mg bid or placebo, ANA598 800 mg bid or placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • New York, New York • San Antonio, Texas
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- IPH2101
- Drug
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio + 2 more
- Conditions
- Infection, Human Immunodeficiency Virus I, HIV-1 Infection
- Interventions
- Physician determined comparator PI + ritonavir, GW640385 + ritonavir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fountain Valley, California + 20 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- PEGylated recombinant interleukin 29 (PEG-rIL-29)
- Drug
- Lead sponsor
- ZymoGenetics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 6 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- 3BNC117-LS, 10-1074-LS
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Physical Activity
- Interventions
- 6-week basic dog obedience training course
- Behavioral
- Lead sponsor
- University of Massachusetts, Amherst
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Amherst, Massachusetts
- Conditions
- Advanced Squamous Tumors
- Interventions
- ABBV-711, Budigalimab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Chicago, Illinois + 3 more
- Conditions
- Cancer
- Interventions
- MEDI-575
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
- Conditions
- Diabetes Mellitus Type 2 in Obese, Obesity
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Insulin Sensitivity, Obesity, Sedentary Lifestyle
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
- Interventions
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 20
- States / cities
- Duarte, California • San Francisco, California • Aurora, Colorado + 15 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- BAY 3547926, BAY 3547922, BAY 3713391, BAY 3713389
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 2
- States / cities
- Dothan, Alabama • Duarte, California
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- Evidation Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- Type 2 Diabetes Mellitus, Obesity
- Interventions
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Procedure · Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertension
- Interventions
- fenofibrate, Placebo
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- IMP9064
- Drug
- Lead sponsor
- Impact Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • New York, New York • Greenville, South Carolina + 1 more
- Conditions
- Obesity, Inflammation
- Interventions
- Grape powder, followed by placebo powder, Placebo powder followed by grape powder
- Dietary Supplement
- Lead sponsor
- USDA, Western Human Nutrition Research Center
- Federal
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Hepatitis C, Chronic
- Interventions
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
- Conditions
- HIV -1 Infection
- Interventions
- BNT351, Placebo
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
- Conditions
- Locally Advanced / Metastatic Solid Tumors
- Interventions
- CR-001
- Drug
- Lead sponsor
- Crescent Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Interventions
- rTMS, Sham rTMS, MRI scan
- Device · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 35 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- HIV Infection, Hepatitis C Infection
- Interventions
- Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Hepatitis C
- Interventions
- Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more